Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tulisokibart Form 1 · 1 trial · 1 indication
Blood samples will be collected to determine the AUC0-inf of tulisokibart.
Blood samples will be collected to determine the AUC0-last of tulisokibart.
Blood samples will be collected to determine the Cmax of tulisokibart.
| Arm | Type | Description |
|---|---|---|
| Arm 1: Tulisokibart Form 1 | EXPERIMENTAL | Participants will receive tulisokibart form 1. |
| Arm 2: Tulisokibart Form 2 | EXPERIMENTAL | Participants will receive tulisokibart form 2. |
| Name | Type | Description |
|---|---|---|
| Tulisokibart Form 1 | BIOLOGICAL | Solution for injection. |
| Tulisokibart Form 2 | BIOLOGICAL | Solution for injection. |
Inclusion Criteria The main inclusion criteria include but are not limited to the following: * Has a body-mass index (BMI) between 18 and 32 kg/m\^2 Exclusion Criteria The main exclusion criteria include but are not limited to the following: * Has a history of more than 1 episode of herpes zost...
Tulisokibart Form 1 is an investigational monoclonal antibody being studied in healthy participants. It is currently in Phase 1 clinical development, and the ongoing trial is evaluating its safety and tolerability in healthy volunteers. It is not approved for any indication and remains in early-stage clinical testing.
Tulisokibart Form 1 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting a Phase 1 clinical trial of this investigational monoclonal antibody in healthy participants.
Tulisokibart Form 1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is active but not recruiting participants, and it is studying the drug in healthy volunteers.
Tulisokibart Form 1 is being studied in one active Phase 1 clinical trial with the identifier NCT07405177. The trial, titled 'A Study of MK-7240 in Healthy Participants (MK-7240-009)', is enrolling 330 healthy participants in Australia and is currently active but not recruiting.
Yes, Tulisokibart Form 1 is also known as MK-7240. The ongoing Phase 1 clinical trial NCT07405177 is titled 'A Study of MK-7240 in Healthy Participants', confirming that MK-7240 is the alternative name for this investigational monoclonal antibody.